Doctor Thomas Frye currently serves as Associate Professor of Urology and Vice Chair of Clinical Affairs for the Department of Urology at the University of Rochester Medical Center. Dr. Frye, is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of prostate and kidney cancers), and advanced open pelvic and retroperitoneal cancer surgery. He has a special interest and expertise in the management of localized prostate cancer with focal therapy. Dr. Frye has the most comprehensive focal therapy program in upstate New York and offers High Intensity Focused Ultrasound (HIFU), cryotherapy, as well as other ablative technologies. He also participates in national clinical trials evaluating the efficacy of focal therapy for prostate cancer.

Dr. Frye was the valedictorian of his class where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine. He went on to complete his urology residency at Southern Illinois University School of Medicine. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.

Dr. Frye’s research projects focus on optimizing the screening, diagnosis and treatment of men with prostate cancer. During his fellowship, he worked extensively in refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interest also includes advanced imaging for prostate cancer as well as focal therapy of prostate cancer.

Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), Society of Urologic Oncology (SUO), American Society of Clinical Oncology, and Focal Therapy Society.

Certified Specialties

Urology - American Board of Urology

Faculty Appointments

Associate Professor - Department of Urology (SMD)

Credentials

Residency & Fellowship

Fellowship, Urologic Oncology, National Cancer Institute/National Institute of Health. 2014 - 2016

Residency, Urology, Southern Illinois University School Of Medicine. 2010 - 2014

Internship, Urology, Southern Illinois University School Of Medicine. 2009 - 2010

Education

DO | Midwestern University. 2009

Research

Clinical Trials

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Lead Researcher: Thomas P Frye

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to othe...

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

Lead Researcher: Thomas P Frye

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Publications

Journal Articles

Robot-assisted Synchronous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease: A Stepwise Description of Technique.

Gurung PMS, Frye TP, Rashid HH, Joseph JV, Wu G

Urology.. 2021 July 153 :333-338. Epub 06/17/2020.

Multi-institutional validation of a perfused robot-assisted partial nephrectomy procedural simulation platform utilizing clinically relevant objective metrics of simulators (CROMS).

Ghazi A, Melnyk R, Hung AJ, Collins J, Ertefaie A, Saba P, Gurung P, Frye T, Rashid H, Wu G, Mottrie A, Costello T, Dasgupta P, Joseph J

BJU international.. 2021 June 127 (6):645-653. Epub 10/06/2020.

Incorporation and validation of clinically relevant performance metrics of simulation (CRPMS) into a novel full-immersion simulation platform for nerve-sparing robot-assisted radical prostatectomy (NS-RARP) utilizing three-dimensional printing and hydrogel casting technology.

Witthaus MW, Farooq S, Melnyk R, Campbell T, Saba P, Mathews E, Ezzat B, Ertefaie A, Frye TP, Wu G, Rashid H, Joseph JV, Ghazi A.

BJU Int. 2020; .

Cribriform pattern and perineural invasion on MR/US fusion biopsy predict failure of selection criteria for prostatic hemigland ablation

Mithal P, Truong M, Quarrier S, Lu D, Hollenberg G, Weinberg E, Miyamoto H, Frye T.

Urol Oncol. 2020; .

Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging

Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM.

Eur Urol Oncol. 2019; .

Sonographic Diagnosis of Unilateral Synchronous Testicular Tumors

Forrest A, Numbere N, Jean-Gilles J, Frye T, Dogra V.

Am J Sonogr. 2019; .

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D

Bladder cancer.. 2018 October 34 (Suppl 1):S1-S43. Epub 10/03/2018.

A Comprehensive Analysis of Cribriform Morphology on MR/US Fusion Biopsy Correlated with Radical Prostatectomy Specimens.

Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

Journal of Urology. 2018; .

Historical and contemporary perspectives on cribriform morphology in prostate cancer.

Truong M, Frye T, Messing E, Miyamoto H.

Nat Rev Urol. 2018; .

Magnetic resonance imaging detection of prostate cancer in men with previous negative prostate biopsy.

Truong M;Frye TP.

Transl Androl Urol. 2017; 6(3): 424-431.

MRI-TRUS Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer

Frye TP, George A, Kilchevsky A, Maruf M, Siddiqui M, Kongnyuy M, Muthigi A, Han H, Parnes H, Merino M, Choyke P, Turkbey B, Wood B, Pinto P.

Journal of Urology. 2017; .

Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology

Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

Journal of Urology. 2017; .

The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy

Maruf M, Fascelli M, George AK, Siddiqui MM, Kongnyuy M, DiBianco JM, Muthigi A, Valayil S, Sidana A, Frye TP, Kilchevsky A, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

Prostate Cancer Prostatic Dis. 2017; .

Prostate Cancer Diagnosis on repeat MRI-TRUS Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling

Chelluri R, Kilchevsky A, George AK, Sidana A, Frye TP, Su D, Fascelli M, Ho R, Abboud SF, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA.

J Urol. 2016; : pii: S0022-5347(16)00327-X. doi: 10.1016.

Reproducibility of Multiparametric MRI and Fusion-Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort

Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA.

J Urol. 2016; pii: S0022-5347(16)00129-4.

Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort.

Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA.

Journal of Urology. 2016; .

The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men

Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Fascelli M, Kadakia M, Frye TP, Ho R, Mertan F, Minhaj Siddiqui M, Su D, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

Urol Oncol. 2016; .

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.

18. Muthigi A, Sidana A, George AK, Kongnyuy M, Shakir N, Kadakia M, Maruf M, Frye TP, Mertan F, Su D, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

Int Urol Nephrol. 2016; .

Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy

Ho R, Siddiqui MM, George AK, Frye T, Kilchevsky A, Fascelli M, Shakir NA, Chelluri R, Abboud SF, Walton-Diaz A, Sankineni S, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

PLoS One. 2016; .

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification

Muthigi A, Sidana A, George AK, Kongnyuy M, Shakir N, Kadakia M, Maruf M, Frye TP, Mertan F, Su D, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

Int Urol Nephrol. 2016; .

Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers

Watson MJ, George AK, Maruf M, Frye TP, Muthigi A, Kongnyuy M, Valayil SG, Pinto PA.

Future Oncol. 2016; .

Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis

Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Ho R, Chelluri R, Mertan F, Frye TP, Su D, Merino MJ, Choyke PL, Wood BJ, Pinto PA, Turkbey B.

Urol Oncol. 2016; .

A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis

Kongnyuy M, Frye TP, George AK, et al.

Case Reports in Urology. 2015; .

Combined Biparametric Prostate MRI and Prostate Specific Antigen in the Detection of Prostate Cancer: a Validation Study in a Biopsy Naïve Patient Population

Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, Frye T, Kilchevsky A, Chelluri R, Abboud S, Siddiqui MM, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B.

Urology. 2015; pii: S0090-4295(15)01091-2.

Optimizing Patient Population for MP-MRI and Fusion Biopsy for Prostate Cancer Detection

Frye TP, Pinto PA, George AK.

Curr Urol Rep. 2015; 16(7):50.

The role of MRI in active surveillance for prostate cancer

Fascelli M, George AK, Frye T, Turkbey B, Choyke PL, Pinto PA.

Curr Urol Rep. 2015; 16(6):42.

Impact of County Rurality and Urologist Density on Urologic Cancer Mortality in Illinois

Frye TP, Sadowski DJ, Zahnd WE, Jenkins WD, Dynda DI, Mueller GS, Alanee SR, McVary KT.

J Urol. 2015; 193(5):1608-13.

Conservative management and female gender are associated with increased cancer?specific death in patients with isolated primary urothelial carcinoma in situ.

Alanee S, Bauman J, Dynda D, Frye T, Konety B, Schwartz B.

Eur J Cancer Care (Engl). 2014; .

Robot-Assisted Inguinal Lymphadenectomy for Urethral Carcinoma

Frye TP, Gorbonos A.

J Laparoendoscopic & Advanced Surgical Techniques and Part B: Videoscopy. 2014; .

Ocular Radiation Exposure in Modern Urologic Practice

Taylor ER, Kramer B, Frye TP, Wang S, Schwartz BF, Köhler TSJ.

Urol. 2013; .

Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response

Johnson LE, Frye TP, McNeel DG.

OncoImmunology. 2012; 1;1(9):1546-1556.

Patient Satisfaction of Vacuum Erection Device (VED) Use After Prostate Cancer Treatment: Three and Six Month Outcomes from a VED Registry

Kohler TS, Frye TP, Rewcastle JC, Mulhall JP.

J Sex. Med. 2012; 9:219.

HLA-A2 restricted T-cell epitopes specific for prostatic acid phosphatase

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG . 2010 Jun;.

Cancer Immunol Immunother. 2010; 59(6):943-53.

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.

J Clin Oncol. 2009; 27:4047-4054.

Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T-cells

Johnson LE, Frye TP, Chinnasamy N, Chinnasamy G, and McNeel DG.

Cancer Immunol Immunother. 2007; 56(6):885-95.

Safety and immunological efficacy of prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DGVaccine.

2006; 24:293-303.

New approaches to identification of antigenic candidates for future prostate cancer immunotherapy

Dunphy EJ, Johnson LE, Olson BM, Frye TP, McNeel DG.

Update on Cancer Therapeutics. 2006; 22:273-284.

Books

Neuropsychology of Cancer and Oncology (2012)

Chapter: Neuropsychology of Genitourinary Malignancies

Authors: Frye TP, Miller J, Tarter TH

Publisher: Springer Publishing Company 2012

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

4.9

During this visit, did this provider show respect for what you had to say?

4.9

During this visit did this provider give you easy to understand information about these health questions or concerns?

4.9

During this visit, did this provider listen carefully to you?

4.9

During this visit, did this provider explain things in a way that was easy to understand?

4.9

Patient Comments

Good

Aug 25, 2024

Informed me of my options and status.

Aug 12, 2024

Dr Frye is very good at listening. He is an excellent urologist.

Jul 28, 2024

5.0

Per my prior comments both Dr. Frye and PA Amanda Buckner were excellent with care provided, interpreting data and test results and communicating a plan. Thank you.

Jul 06, 2024

5.0

Excellent

Jun 30, 2024

5.0

I have recommended 2 people who have since hd appointments with Dr. Frye

Jun 11, 2024

5.0

Dr and staff had my interests in mind!

Jun 10, 2024

5.0

I have recommended him

Jun 01, 2024

5.0

Felt vert good with results

May 12, 2024

5.0

Dr. Frye is very knowledgable and competent as a health practitioner. He was very thorough when going over my recent test results - PSA and Urinalysis. He has a very fine caring manner and is really personable. I have a high degree of confidence in him.

Mar 12, 2024

5.0

The entire team that works with Dr Frye are all very good and always listen to what I have to say.

Jan 06, 2024

5.0

Excellent physician!!

Dec 14, 2023

5.0

Dr Frye and his staff are terrific

Nov 11, 2023

Excellent Doctor and Nurse experience. Answered all my questions and showed compassion and concern for my issues. I would recommend U of R Urological services and doctors to everyone

Oct 30, 2023

5.0

Doctor Frye showed great empathy, and provided options for care, along with understandable reasons for those options.

Oct 21, 2023

5.0

This Dr did my surgery and I would recommend him to others.

Sep 28, 2023

5.0

No complaints

Sep 24, 2023

5.0

A thorough explanation of treatment options was given

Aug 05, 2023

5.0

Based on my initial encounter, Dr. Frye is a first rate practitioner.

Jul 29, 2023

5.0

Everything was very good

Jul 14, 2023

5.0

I have recommended Dr Frye many times

Jun 25, 2023

3.0

We felt that Dr. Frye was in a hurry gave us the feeling of why we were there. [...]

Jun 12, 2023

5.0

Both the doctor and PA explained a prospective procedure to me, and did not pressure me to undergo it until I felt I needed it.

May 31, 2023

5.0

He is a good doctor who seems to care about his patients. I am glad to have him as a surgeon

May 29, 2023

5.0

The Dr. Was Excellent.

May 05, 2023

5.0

Good

Apr 23, 2023

5.0

Dr. Frye listened, expalined all questions to my complete satisfaction

Mar 22, 2023

5.0

The Dr is very good. He listens to my problems and address them. He is excellent

Feb 13, 2023

5.0

Dr Frye and his team have been great.

Feb 09, 2023

Dr. Frye was very generous with his time and very responsive to my questions. His presentation about treatment options was very cogent and candid.

Feb 03, 2023

5.0

Both the PA and doctor were very good.The PA explained things from my lab test and answered my questions.

Jan 26, 2023

5.0

Dr. Frye is an excellent doctor. He is professional, friendly and helpful. He is a definite asset to URMC.

Jan 16, 2023

5.0

I have the highest regard for Dr. Frye. He has guided me through the process of treating my prostate cancer, from beginning to end, with the utmost degree of professionalism and sense of care. I cannot thank him enough, and am grateful to have had him as my urologist.

Dec 20, 2022

5.0

Dr. Frye was excellent.

Dec 17, 2022

5.0

Dr. Frye was attentive to detail on my biopsy results and addressed my concern of possible prostate cancer. He ordered a PSA bloodtest.

Nov 16, 2022

5.0

This Dr is very good. He listened to my problems and provided a direction to go

Oct 30, 2022

5.0

More tests were needed and he wanted to consult w/colleagues - He quickly followed up when both those pieces were available.

Oct 19, 2022

5.0

My experience with Dr. Frye was excellent

Oct 15, 2022

3.8

Good Experience

Sep 22, 2022

5.0

The Dr reviewed the surgery and biopsy and told me what is to be done in the future. He exudes confidence and I was pleased to have him as my surgeon

Sep 18, 2022

5.0

Dr Frye was pretty cut & dry about my situation, but I appreciate that - I asked about different tests but he responded with practical experience from similar cases and I agreed that it seemed like the right way to go

Sep 07, 2022

5.0

I trust Dr. Frye and his team with my life!

Sep 05, 2022

I admire his confidence

Aug 27, 2022

5.0

AGAIN, I KNOW YOU ARE PRETTY BUSY, AND I AM ENCOURAGED NOW, BUT IT TOOK A LONG TIME TO GET TO THIS POINT IN MY CARE. I WAS REALLY WORRIED, NOW I FEEL I HAVE A GOOD CHANCE TO GET BETTER!

Aug 24, 2022

5.0

Dr. Frye answered all my questions; gave me a lot of good information, put me at ease; explained everything he told me. He's caring, kind, very patient, and I'm very happy & confident with him as my doctor.

Aug 15, 2022

5.0

Provider was Good .

Aug 03, 2022

5.0

Good very informative

Jul 23, 2022

5.0

I don't think my experience could be better Dr Frye used techniques for minimal pain and quick recovery

Jul 10, 2022

1.4

Dr. Frye may be excellent at surgery but he needs to work on his interpersonal skills. He asked me my symptoms then interrupted me when I started talking about them to tell me nothing is wrong. He didn't explain his impression well, didn't ask if I had questions. Even if he's correct in his assessment, if a patient doesn't feel heard the patient will be unsatisfied with the impression. [...] I'm not sure how much my opinion matters in the long run. I'm just one patient, he apparently does well enough at his job that my job seems like a hobby and the rest of the world doesn't matter. I'll keep the rest of my impression to myself.

Jul 08, 2022

5.0

Excellent experience with Dr. Frye.

Feb 23, 2022